ten23 health has officially opened its VIVA2 facility in Visp, Switzerland.
VIVA2 will significantly enhance the company's commercial and clinical production capabilities — including the fill/finish of vials, syringes and cartridges.
The site will also have dedicated quality control microbiology labs, as well as related office space.
The facility houses two sterile manufacturing lines, including a large-scale commerical and clinical filling line for ready-to-use (RTU) primary packaging for syringes, cartridges and vials.
ten23 health has also installed a clinical to commercial bulk vial filling line, which has two lypophilisers suitable for large-scale projects.
The filling lines are fully automated, allowing optimal procesing, as well as 100% fill weight control and stopper setting precision for syringes and cartridges.
Glass or polymer containers can be processed by the site, as well as ultra-viscous formulations for subcutaneous indications.
The expansion will also open up skilled employment opportunities in the Valais area.
ten23 health's CEO, Dr Hanns-Christian Mahler, commented: "I am proud and excited about the grand opening of our VIVA2 facility. This is the start of something great, and VIVA2's capabilities for sterile manufacturing will be a key opportunity to supply essential medicines to patients,"
